Merck & Co., Inc. stock (US58933Y1055): Key takeaways from the latest Keytruda and pipeline updates

New data on cancer blockbuster Keytruda and fresh pipeline updates keep Merck & Co., Inc. in focus. What the latest news could mean for growth prospects, patent risks and US-focused healthcare investors.

Merck & Co., Inc. has remained in the spotlight after a series of recent updates around its cancer drug Keytruda and broader pipeline, including new clinical data and regulatory milestones reported in April and May 2025, according to company disclosures and major financial media reports. These developments come as the group continues to prepare for future patent expiries while seeking to extend growth through oncology, vaccines and animal health, as noted by Merck investor communications as of 04/25/2025 and coverage by Reuters as of 05/10/2025.

As of: 25.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals, biotechnology, healthcare
• Headquarters/country: Kenilworth, New Jersey, United States
• Core markets: Global prescription drugs, US healthcare market, vaccines, animal health
• Key revenue drivers: Oncology therapies such as Keytruda, vaccines like Gardasil, hospital acute care products
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co., Inc.: core business model

Merck & Co., Inc. is one of the largest US-based pharmaceutical groups, focusing on prescription drugs, vaccines and animal health products. The company generates a significant share of its revenue from oncology, in particular through its immuno-oncology therapy Keytruda, which has expanded into multiple cancer indications over the last decade, as outlined in company filings and annual reports referenced by Merck annual filings as of 02/22/2025.

Beyond oncology, Merck maintains a substantial vaccines franchise, including human papillomavirus vaccine Gardasil, and a hospital acute care portfolio. These businesses help diversify earnings across therapeutic areas and geographies, which can partially mitigate risks from individual product cycles. According to company commentary in 2024 and 2025 earnings materials, Merck continues to prioritize research and development spending to sustain a robust late-stage pipeline, as cited by Merck presentations as of 05/01/2025.

Another important pillar of the business is animal health, where Merck markets vaccines and medicines for livestock and companion animals. This division offers exposure to global protein demand and pet ownership trends and provides a revenue stream that is not directly tied to the same patent cycles as human pharmaceuticals, according to disclosures in the company’s segmented reporting, as summarized by SEC filings as of 02/22/2025.

Main revenue and product drivers for Merck & Co., Inc.

The most important single product for Merck in recent years has been Keytruda, a PD-1 inhibitor used in the treatment of various cancers such as melanoma, lung cancer and head and neck cancer. Keytruda has been approved in dozens of markets and indications, and its label has continued to expand following positive Phase 3 data in additional tumor types, a trend highlighted in oncology updates released in early 2025, according to Merck news as of 04/25/2025.

Vaccines form the second major revenue stream. Gardasil and Gardasil 9, which protect against human papillomavirus, have seen demand in both developed and emerging markets. Merck has indicated ongoing investments to expand manufacturing capacity for these vaccines, aiming to serve growing demand and fulfill long-term supply commitments, as noted in manufacturing updates and capital expenditure commentary in 2024 and 2025, summarized by Merck news releases as of 03/18/2025.

In addition, hospital acute care products, including treatments for infectious diseases and cardiovascular conditions, contribute meaningful sales. Some of these therapies face generic competition or will do so later this decade, leading Merck to emphasize newer launches and lifecycle management strategies. The company has also communicated that it is actively evaluating business development opportunities, such as licensing deals and acquisitions, to supplement internal R&D, as mentioned in management remarks around quarterly results in 2025, according to Reuters as of 05/02/2025.

Conclusion

Merck & Co., Inc. remains closely watched in global equity markets due to its reliance on Keytruda, its expanding vaccines and animal health portfolios, and ongoing regulatory and clinical milestones. The latest oncology data and pipeline updates underscore opportunities to extend growth but also highlight the importance of continued innovation as key patents approach expiry later in the decade. For US investors following large-cap healthcare stocks, Merck’s mix of blockbuster products, R&D intensity and exposure to the US and international healthcare systems provides both potential upside and risks that depend on scientific, regulatory and competitive outcomes.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.